DAIC
MARCH 14, 2025
The Transplant Company recently announced that AlloSureis now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (SPK) transplant. 5 As with other organ transplants, the organs are at risk of rejection.
Medical Xpress - Cardiology
FEBRUARY 15, 2024
More than 4,500 heart transplants were performed in the U.S. While the lifesaving operation improves the quality of life and longevity for most recipients, organ rejection remains a risk, with acute rejection occurring in up to 32% of recipients within the first year.
Frontiers in Cardiovascular Medicine
FEBRUARY 19, 2025
At present, the main methods to treat ischemic heart disease are drug therapy, intervention and operation. These methods only alleviate symptoms of heart failure and myocardial ischemia and improve patients' quality of life by partially restoring myocardial reperfusion.
DAIC
FEBRUARY 21, 2024
Getty Images milla1cf Wed, 02/21/2024 - 19:10 February 21, 2024 — Ochsner Children's Hospital , ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices. Yet, research and innovation in this field has not kept pace.
DAIC
APRIL 16, 2024
Dr. JoAnn Lindenfeld of Vanderbilt University presented analysis showing that patients with Barostim + GDMT had sustained and significant improvements in quality-of-life scores (MLWHF and EQ-5D) and many subdomains of these scores (e.g., See more details at TCTMD. versus patients on GDMT alone.
DAIC
MARCH 13, 2024
In the subgroup of patients targeted in the CardiAMP Heart Failure II Trial, results showed large absolute and relative risk reduction of heart death equivalents of the patients in the treated group. Treated patients also had reduced major adverse cardiac events and greatly improved quality of life. “We
European Journal of Heart Failure
NOVEMBER 11, 2024
Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx). CASTLE-VT will randomize 160 patients with a follow-up period of 2years.
Expert insights. Personalized for you.
80 
Let's personalize your content